Gaucher Disease - Pipeline Review, H1 2020

June 2020 | 105 pages | ID: GB7D0CAE22DEN
Global Markets Direct

Abstracts

Gaucher Disease - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease - Pipeline Review, H1 2020, provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape.
Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue and seizures. Treatment includes enzyme replacement therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gaucher Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 6, 11 and 6 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 5 molecules, respectively.
Gaucher Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Gaucher Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gaucher Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gaucher Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gaucher Disease (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gaucher Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Gaucher Disease - Overview
Gaucher Disease - Therapeutics Development
Gaucher Disease - Therapeutics Assessment
Gaucher Disease - Companies Involved in Therapeutics Development
Gaucher Disease - Drug Profiles
Gaucher Disease - Dormant Projects
Gaucher Disease - Discontinued Products
Gaucher Disease - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Gaucher Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Gaucher Disease - Pipeline by Adienne Pharma & Biotech, H1 2020
Gaucher Disease - Pipeline by Apollo Therapeutics LLC, H1 2020
Gaucher Disease - Pipeline by AVROBIO Inc, H1 2020
Gaucher Disease - Pipeline by Belrose Pharma Inc, H1 2020
Gaucher Disease - Pipeline by Bioasis Technologies Inc, H1 2020
Gaucher Disease - Pipeline by Biosidus SA, H1 2020
Gaucher Disease - Pipeline by Blue Turtle Bio Technologies Inc, H1 2020
Gaucher Disease - Pipeline by Erad Therapeutics Inc, H1 2020
Gaucher Disease - Pipeline by Evox Therapeutics Ltd, H1 2020
Gaucher Disease - Pipeline by Freeline Therapeutics Ltd, H1 2020
Gaucher Disease - Pipeline by Generation Bio Co, H1 2020
Gaucher Disease - Pipeline by Genzyme Corp, H1 2020
Gaucher Disease - Pipeline by GT Gain Therapeutics SA, H1 2020
Gaucher Disease - Pipeline by ILIAS Biologics Inc, H1 2020
Gaucher Disease - Pipeline by ISU ABXIS Co Ltd, H1 2020
Gaucher Disease - Pipeline by Johnson & Johnson, H1 2020
Gaucher Disease - Pipeline by M6P Therapeutics, H1 2020
Gaucher Disease - Pipeline by Orphazyme A/S, H1 2020
Gaucher Disease - Pipeline by Prevail Therapeutics Inc, H1 2020
Gaucher Disease - Pipeline by Sanofi, H1 2020
Gaucher Disease - Pipeline by SmartPharm Therapeutics Inc, H1 2020
Gaucher Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Gaucher Disease - Pipeline by Vera Therapeutics Inc, H1 2020
Gaucher Disease - Pipeline by Yuhan Corp, H1 2020
Gaucher Disease - Dormant Projects, H1 2020
Gaucher Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
Gaucher Disease - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gaucher Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Adienne Pharma & Biotech
Apollo Therapeutics LLC
AVROBIO Inc
Belrose Pharma Inc
Bioasis Technologies Inc
Biosidus SA
Blue Turtle Bio Technologies Inc
Erad Therapeutics Inc
Evox Therapeutics Ltd
Freeline Therapeutics Ltd
Generation Bio Co
Genzyme Corp
GT Gain Therapeutics SA
ILIAS Biologics Inc
ISU ABXIS Co Ltd
Johnson & Johnson
M6P Therapeutics
Orphazyme A/S
Prevail Therapeutics Inc
Sanofi
SmartPharm Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Vera Therapeutics Inc
Yuhan Corp